About US
Contact us
-
China speaks on GSK bribery charges, and the word isn't goodChina is coming down hard on GlaxoSmithKline's ($GSK) local operation. After a months-long bribery probe,Chinesepolice have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top2014/5/15
-
Akorn agrees to buy VersaPharmUS-based Akorn has entered into a definitive agreement to acquire VPI Holdings, the parent company of VersaPharm, for $440m in cash. The privately held developer and marketer of multi-source prescrip2014/5/14
-
Bayer's Kogenate FS gets FDA approval for routine prophylaxis in Hemophilia A patientsBayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication of its Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to preve2014/5/14
-
AbbVie seeks EMA approval for marketing interferon-free hepatitis C therapy in EUUS-based biopharmaceutical firm AbbVie has submitted marketing authorisation applications (MAAs) to the European Medicines Agency (EMA) seeking approval for its investigational, all-oral, interferon-f2014/5/13
-
GSK and Theravance announce European approval for chronic obstructive pulmonary disease drugGlaxoSmithKline (GSK) and Theravance have announced the European Commission's marketing approval for Anoro (umeclidinium/vilanterol) for the treatment of chronic obstructive pulmonary disease (COPD).2014/5/13
-
NIH Study Demonstrates that a New Cancer Immunotherapy Method could be Effective Against a Wide Range of CancersA new method for using immunotherapy to specifically attack tumour cells that have mutations unique to a patient’s cancer has been developed by scientists at the National Cancer Institute (NCI), part2014/5/12
-
Janssen submits sNDA to FDA for genotype 1 chronic hepatitis C drugJanssen Research & Development has submitted a supplemental new drug application (sNDA) to US Food and Drug Administration (FDA) for Olysio (simeprevir) for once-daily use in combination with sofo2014/5/12
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua2014 PhexTour（Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua, was successfully concluded on 15 April at Hemei Jinpan Hotel . More than 100 technical persons from 22014/5/12
-
FDA to review Merck’s biologics licence application for advanced melanoma productThe US Food and Drug Administration (FDA) has accepted Merck's biologics licence application for review of its MK-3475, an investigational anti-PD-1 antibody, for advanced melanoma. The investigation2014/5/9
-
Pfizer’s takeover bid for AstraZeneca raises concerns in UKPfizer's takeover bid of AstraZeneca has raised concerns regarding the company's commitment to research and development, as well as potential job losses in UK drug research. Pfizer has said that toge2014/5/9